These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Retrospective inter- and intra-patient evaluation of trabectedin after best supportive care for patients with advanced translocation-related sarcoma after failure of standard chemotherapy. Araki N; Takahashi S; Sugiura H; Ueda T; Yonemoto T; Takahashi M; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Kawai A Eur J Cancer; 2016 Mar; 56():122-130. PubMed ID: 26845175 [TBL] [Abstract][Full Text] [Related]
10. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice. Le Cesne A; Reichardt P Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310 [TBL] [Abstract][Full Text] [Related]
11. Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study. Vincenzi B; Stumbo L; Maltese G; Cerbone L; Spalato Ceruso M; Badalamenti G; Santini D; Tonini G; Frezza AM; De Lisi D; Silletta M Sci Rep; 2015 Aug; 5():12077. PubMed ID: 26235506 [TBL] [Abstract][Full Text] [Related]
12. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma. Simpson EL; Rafia R; Stevenson MD; Papaioannou D Health Technol Assess; 2010 May; 14 Suppl 1():63-7. PubMed ID: 20507805 [TBL] [Abstract][Full Text] [Related]
13. Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis. Schmitt T; Keller E; Dietrich S; Wuchter P; Ho AD; Egerer G Mar Drugs; 2010 Oct; 8(10):2647-58. PubMed ID: 21116412 [TBL] [Abstract][Full Text] [Related]
14. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis. Taieb S; Saada-Bouzid E; Tresch E; Ryckewaert T; Bompas E; Italiano A; Guillemet C; Peugniez C; Piperno-Neumann S; Thyss A; Maynou C; Clisant S; Penel N; Eur J Cancer; 2015 Jan; 51(2):202-9. PubMed ID: 25499439 [TBL] [Abstract][Full Text] [Related]
15. Trabectedin for advanced soft tissue sarcomas: a single institution experience. Gounaris I; Hatcher HM; Davidson D; Sherbourne K; Alam S; Zaki KA; Horan G; Earl HM Future Oncol; 2014 Aug; 10(11):1843-51. PubMed ID: 24450573 [TBL] [Abstract][Full Text] [Related]
16. Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials. Cesne AL; Judson I; Maki R; Grosso F; Schuetze S; Mehren MV; Chawla SP; Demetri GD; Nieto A; Tanovic A; Blay JY Br J Cancer; 2013 Oct; 109(7):1717-24. PubMed ID: 24022187 [TBL] [Abstract][Full Text] [Related]
17. Going further in the knowledge of Yondelis®; what's new in daily clinical practice? Blay JY Future Oncol; 2014 Jun; 10(8 Suppl):s13-7. PubMed ID: 25048044 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution. Fayette J; Boyle H; Chabaud S; Favier B; Engel C; Cassier P; Thiesse P; Méeus P; Sunyach MP; Vaz G; Ray-Coquard I; Ranchère D; Decouvelaere AV; Alberti L; Pérol D; Blay JY Anticancer Drugs; 2010 Jan; 21(1):113-9. PubMed ID: 19887935 [TBL] [Abstract][Full Text] [Related]
19. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558 [TBL] [Abstract][Full Text] [Related]